ELANIX BIOTECHNOLOGIES AG securing funding, adding staff and moving to larger offices
Favorable conditions are in place for merger-arbitrage ETFs, including increasing M&A activity and the likelihood of higher interest rates.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
We'd prefer a pack of gum to these businesses.
Three ways to separate long-term winners from stocks that fizzle.